In silico ascription of gene expression differences to tumor and stromal cells in a model to study impact on breast cancer outcome

PLoS ONE

Volumn 5, Issue 11, 2010, Pages

  Myhre, Simen ^a,b   Mohammed, Hayat ^a,c   Tramm, Trine ^d   Alsner, Jan ^d   Finak, Greg ^e   Park, Morag ^e   Overgaard, Jens ^d   Børresen Dale, Anne Lise ^a,b   Frigessi, Arnoldo ^c   Sørlie, Therese ^a,b  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b UNIVERSITY OF OSLO   (Norway)

^c UNIVERSITY OF OSLO   (Norway)

^d AARHUS UNIVERSITY HOSPITAL   (Denmark)

^e MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; FLUOROURACIL; MESSENGER RNA; METHOTREXATE; TAMOXIFEN; PHOSPHOTRANSFERASE; PIP4K2A PROTEIN, HUMAN;

ARTICLE; BREAST CANCER; CARCINOMA CELL; CELL FRACTIONATION; COMPUTER MODEL; CONTROLLED STUDY; DISTANT METASTASIS; EPITHELIUM CELL; FEMALE; GENE EXPRESSION; GENE IDENTIFICATION; GENE PROBE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LASER CAPTURE MICRODISSECTION; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OUTCOME ASSESSMENT; RNA TRANSCRIPTION; STATISTICAL ANALYSIS; STROMA CELL; TUMOR CELL; ADULT; BREAST TUMOR; DNA MICROARRAY; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; METASTASIS; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROGNOSIS;

ADULT; BREAST NEOPLASMS; EPITHELIAL CELLS; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASM METASTASIS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OUTCOME ASSESSMENT (HEALTH CARE); PHOSPHOTRANSFERASES (ALCOHOL GROUP ACCEPTOR); PROGNOSIS; STROMAL CELLS;

EID: 78649524955     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0014002     Document Type: Article

References (37)

1. Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24: 2137-2150.
2. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V (2007) Descriptive analysis of estrogen receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive breast cancer, the so-called triple-negative phenotype: a population-based study from the California cancer Registry. Cancer 109: 1721-1728.
3. Eisen MB, Brown PO (1999) DNA arrays for analysis of gene expression. Methods Enzymol 303: 179-205.
4. Perou CM, Sorlie T, Eisen MB, van de RM, Jeffrey SS, et al. (2000) Molecular portraits of human breast tumours. Nature 406: 747-752.
5. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, et al. (2001) Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98: 10869-10874.
6. Sorlie T, Tibshirani R, Parker J, Hastie T, Marron JS, et al. (2003) Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci U S A 100: 8418-8423.
7. van't Veer LJ, Dai H, van de Vijver MJ, He YD, Hart AA, et al. (2002) Gene expression profiling predicts clinical outcome of breast cancer. Nature 415: 530-536.
8. Cardoso F, Saghatchian M, Thompson A, Rutgers E (2008) Inconsistent criteria used in American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. J Clin Oncol 26: 2058-2059.
9. Paik S, Shak S, Tang G, Kim C, Baker J, et al. (2004) A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer. N Engl J Med 351: 2817-2826.
10. Paik S, Tang G, Shak S, Kim C, Baker J, et al. (2006) Gene expression and benefit of chemotherapy in women with node-negative, estrogen receptorpositive breast cancer. J Clin Oncol 24: 3726-3734.
11. Sparano JA, Paik S (2008) Development of the 21-gene assay and its application in clinical practice and clinical trials. J Clin Oncol 26: 721-728.
12. van de Vijver MJ, He YD, van't Veer LJ, Dai H, Hart AA, et al. (2002) A geneexpression signature as a predictor of survival in breast cancer. N Engl J Med 347: 1999-2009.
13. Radisky D, Hagios C, Bissell MJ (2001) Tumors are unique organs defined by abnormal signaling and context. Semin Cancer Biol 11: 87-95.
14. Bissell MJ, Radisky DC, Rizki A, Weaver VM, Petersen OW (2002) The organizing principle: microenvironmental influences in the normal and malignant breast. Differentiation 70: 537-546.
15. Finak G, Bertos N, Pepin F, Sadekova S, Souleimanova M, et al. (2008) Stromal gene expression predicts clinical outcome in breast cancer. Nat Med 14: 518-527.
16. Sugiyama Y, Farrow B, Murillo C, Li J, Watanabe H, et al. (2005) Analysis of differential gene expression patterns in colon cancer and cancer stroma using microdissected tissues. Gastroenterology 128: 480-486.
17. Cleator SJ, Powles TJ, Dexter T, Fulford L, Mackay A, et al. (2006) The effect of the stromal component of breast tumours on prediction of clinical outcome using gene expression microarray analysis. Breast Cancer Res 8: R32.
18. Stuart RO, Wachsman W, Berry CC, Wang-Rodriguez J, Wasserman L, et al. (2004) In silico dissection of cell-type-associated patterns of gene expression in prostate cancer. Proc Natl Acad Sci U S A 101: 615-620.
19. Tusher VG, Tibshirani R, Chu G (2001) Significance analysis of microarrays applied to the ionizing radiation response. Proc Natl Acad Sci U S A 98: 5116-5121.
20. Farmer P, Bonnefoi H, Anderle P, Cameron D, Wirapati P, et al. (2009) A stroma-related gene signature predicts resistance to neoadjuvant chemotherapy in breast cancer. Nat Med 15: 68-74.
21. Franzen LE, Ekstedt M, Kechagias S, Bodin L (2005) Semiquantitative evaluation overestimates the degree of steatosis in liver biopsies: a comparison to stereological point counting. Mod Pathol 18: 912-916.
22. Carter CJ (2007) Multiple genes and factors associated with bipolar disorder converge on growth factor and stress activated kinase pathways controlling translation initiation: implications for oligodendrocyte viability. Neurochem Int 50: 461-490.
23. Miller MM, James RA, Richer JK, Gordon DF, Wood WM, et al. (1997) Progesterone regulated expression of flavin-containing monooxygenase 5 by the B-isoform of progesterone receptors: implications for tamoxifen carcinogenicity. J Clin Endocrinol Metab 82: 2956-2961.
24. Blake CA, Brown LM, Duncan MW, Hunsucker SW, Helmke SM (2005) Estrogen regulation of the rat anterior pituitary gland proteome. Exp Biol Med (Maywood) 230: 800-807.
25. De Souza SE, De Bessa SA, Netto MM, Nagai MA (2008) Silencing of LRRC49 and THAP10 genes by bidirectional promoter hypermethylation is a frequent event in breast cancer. Int J Oncol 33: 25-31.
26. Sakaguchi G, Orita S, Maeda M, Igarashi H, Takai Y (1995) Molecular cloning of an isoform of Doc2 having two C2-like domains. Biochem Biophys Res Commun 217: 1053-1061.
27. Wakefield L, Robinson J, Long H, Ibbitt JC, Cooke S, et al. (2008) Arylamine Nacetyltransferase 1 expression in breast cancer cell lines: a potential marker in estrogen receptor-positive tumors. Genes Chromosomes Cancer 47: 118-126.
28. Gonda TJ, Leo P, Ramsay RG (2008) Estrogen and MYB in breast cancer: potential for new therapies. Expert Opin Biol Ther 8: 713-717.
29. Yau WL, Lung HL, Zabarovsky ER, Lerman MI, Sham JS, et al. (2006) Functional studies of the chromosome 3p21.3 candidate tumor suppressor gene BLU/ZMYND10 in nasopharyngeal carcinoma. Int J Cancer 119: 2821-2826.
30. Su LK, Qi Y (2001) Characterization of human MAPRE genes and their proteins. Genomics 71: 142-149.
31. Koda M, Sulkowska M, Kanczuga-Koda L, Jarzabek K, Sulkowski S (2007) Expression of leptin and its receptor in female breast cancer in relation with selected apoptotic markers. Folia Histochem Cytobiol 45 Suppl 1: S187-S191.
32. Tessitore L, Vizio B, Pesola D, Cecchini F, Mussa A, et al. (2004) Adipocyte expression and circulating levels of leptin increase in both gynaecological and breast cancer patients. Int J Oncol 24: 1529-1535.
33. Kyndi M, Overgaard M, Nielsen HM, Sorensen FB, Knudsen H, et al. (2009) High local recurrence risk is not associated with large survival reduction after postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of DBCG 82 b&c. Radiother Oncol 90: 74-79.
34. Nielsen HM, Overgaard M, Grau C, Jensen AR, Overgaard J (2006) Study of failure pattern among high-risk breast cancer patients with or without postmastectomy radiotherapy in addition to adjuvant systemic therapy: longterm results from the Danish Breast Cancer Cooperative Group DBCG 82 b and c randomized studies. J Clin Oncol 24: 2268-2275.
35. Gundersen HJ, Bagger P, Bendtsen TF, Evans SM, Korbo L, et al. (1988) The new stereological tools: disector, fractionator, nucleator and point sampled intercepts and their use in pathological research and diagnosis. APMIS 96: 857-881.
36. Noth S, Benecke A (2005) Avoiding inconsistencies over time and tracking difficulties in Applied Biosystems AB1700/Panther probe-to-gene annotations. BMC Bioinformatics 6: 307.
37. Conover WJ (1999) Practical nonparametric statics. New York: Wiley.